Phase III Gynecologic Oncology Group Study of Advanced Ovarian Cancer: Bevacizumab Added to Initial Chemotherapy Extends Progression-Free Survival | Zendy

AI Assistant Blog Pricing

Open Access

Phase III Gynecologic Oncology Group Study of Advanced Ovarian Cancer: Bevacizumab Added to Initial Chemotherapy Extends Progression-Free Survival

Publication year - 2010

Publication title -

oncology times

Language(s) - English

Resource type - Journals

eISSN - 1548-4688

pISSN - 0276-2234

DOI - 10.1097/01.cot.0000387947.51553.29

Subject(s) - bevacizumab , gynecologic oncology , oncology , medicine , chemotherapy , ovarian cancer , epithelial ovarian cancer , progression free survival , gynecologic cancer , cancer , gynecology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.